These factsheets are presented in memory of our friend Sleep, who contributed so much to creating them. They would not exist without him.

Factsheet data is now cached locally - if you have visited a page you can now view it offline!

Are you a harm reduction organisation using TripSit? Let us know about you!
Notice something wrong with this page? Let us know!

Parafluorofentanyl

parafluorofentanyl

Basic Information

Summary

Rare, little known and extremely potent analogue of Fentanyl developed by Janssen Pharmaceutica in the 1960s. Use with extreme caution and never mix with other depressants.

Opioid

Opioids are pain-killing depressants which may also cause euphoria.

Read more on TripSit Wiki...

Depressant

Depressants are drugs which reduce arousal and stimulation in the user, characterised by a depressing of mental and physical functions.

Read more on TripSit Wiki...

Habit-forming

These drugs pose a higher risk of causing habit forming behaviour, take particular care with the amount and frequency they are taken.

Read more on TripSit Wiki...

Tentative

Drugs marked as tentative are those our team wasn't able to find much reliable information about. This is often because the drug is very new. Information listed under these drugs should not be entirely trusted.

Dose

Insufflated
Light10-25ug
Common25-40ug
Strong40-65ug+

Duration

Oral
Onset5-10 minutes
Duration3-4 hours
After-effects1-4 hours
Insufflated
Onset0-1 minutes
Duration2-3 hours
After-effects1-2 hours

Aliases

pff
4-fluorofentanyl

See TripSit Wiki for more information about drug interactions

Interactions

Dangerous

  • Ketamine
    • Both substances bring a risk of vomiting and unconsciousness. If the user falls unconscious while under the influence there is a severe risk of vomit aspiration if they are not placed in the recovery position.
  • MXE
    • This combination can potentiate the effects of the opioid
  • DXM
    • CNS depression, difficult breathing, heart issues, hepatoxic, just very unsafe combination all around. Additionally if one takes dxm, their tolerance of opiates goes down slightly, thus causing additional synergistic effects.
  • Cocaine
    • Stimulants increase respiration rate allowing a higher dose of opiates. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
  • Alcohol
    • Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. Place affected patients in the recovery position to prevent vomit aspiration from excess. Memory blackouts are likely
  • GHB/GBL
    • The two substances potentiate each other strongly and unpredictably, very rapidly leading to unconsciousness. While unconscious, vomit aspiration is a risk if not placed in the recovery position
  • Tramadol
    • Concomitant use of tramadol increases the seizure risk in patients taking other opioids. These agents are often individually epileptogenic and may have additive effects on seizure threshold during coadministration. Central nervous system- and/or respiratory-depressant effects may be additively or synergistically present
  • Benzodiazepines
    • Central nervous system and/or respiratory-depressant effects may be additively or synergistically present. The two substances potentiate each other strongly and unpredictably, very rapidly leading to unconsciousness. While unconscious, vomit aspiration is a risk if not placed in the recovery position Blackouts/memory loss likely

Caution

  • PCP
    • PCP can reduce opioid tolerance, increasing the risk of overdose
  • N2O
    • Both substances potentiate the ataxia and sedation caused by the other and can lead to unexpected loss of consciousness at high doses. While unconscious, vomit aspiration is a risk if not placed in the recovery position. Memory blackouts are likely.
  • Amphetamines
    • Stimulants increase respiration rate allowing a higher dose of opiates. If the stimulant wears off first then the opiate may overcome the patient and cause respiratory arrest.
  • MAOIs
    • Coadministration of monoamine oxidase inhibitors (MAOIs) with certain opioids has been associated with rare reports of severe and fatal adverse reactions. There appear to be two types of interaction, an excitatory and a depressive one. Symptoms of the excitatory reaction may include agitation, headache, diaphoresis, hyperpyrexia, flushing, shivering, myoclonus, rigidity, tremor, diarrhea, hypertension, tachycardia, seizures, and coma. Death has occurred in some cases.

Low Risk & Increased Effects

Low Risk & No Increased Effects

  • Mushrooms
  • LSD
  • DMT
  • Mescaline
  • DOx
    • No unexpected interactions.
  • NBOMes
  • 2C-x
  • 2C-T-x
    • No expected interactions, some opioids have serotonin action, and could lead to Serotonin Syndrome or a seizure. These are pretty much only to Pentazocine, Methadone, Tramadol, Tapenatdol.
  • αMT
    • No unexpected interactions
  • 5-MeO-xxT
  • MDMA
  • Caffeine
  • SSRIs
    • There have been very infrequent reports of a risk of serotonin syndrome with this combination, though this should not be a practical concern.